anti-inflammatory therapies - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.42 [0.01, 12.75]< 10%1 study (1/-)68.7 %some concernnot evaluable moderatecrucial-
deaths 0.55 [0.19, 1.54]< 10%2 studies (2/-)87.4 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.81 [0.62, 1.04]< 10%2 studies (2/-)95.1 %some concernnot evaluable moderatecrucial-
hospitalization 0.85 [0.54, 1.35]< 114%2 studies (2/-)75.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.53 [0.25, 1.11]< 10%1 study (1/-)95.4 %lownot evaluable highimportant-
recovery 0.92 [0.72, 1.17]> 10%1 study (1/-)24.7 %some concernnot evaluable moderatenon important-

safety endpoints 00

related AE (TRAE) 1.74 [1.50, 2.03]< 10%1 study (1/-)0.0 %lownot evaluable highimportant-
serious adverse events 0.77 [0.60, 1.00]< 10%1 study (1/-)97.4 %lownot evaluable highimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.